NASDAQ:NURO

NeuroMetrix (NURO) Stock Forecast, Price & News

$0.60

-0.02 (-3.31%)

(As of 01:12 PM ET)

Compare

Today's Range: $0.60
▼
$0.63
50-Day Range: $0.64
▼
$0.98
52-Week Range: $0.60
▼
$3.45

Volume: 35,161 shs
Average Volume: 65,720 shs
Market Capitalization: $5.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NURO Price History

30 days | 90 days | 365 days | Advanced Chart

NURO Stock News Headlines

September 20, 2023 | americanbankingnews.com

NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

August 30, 2023 | finance.yahoo.com

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 28, 2023 | finance.yahoo.com

Is NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

July 27, 2023 | finanznachrichten.de

NeuroMetrix, Inc.: NeuroMetrix Reports Q2 2023 Business Highlights

July 27, 2023 | finance.yahoo.com

NeuroMetrix Reports Q2 2023 Business Highlights

July 20, 2023 | finance.yahoo.com

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

July 11, 2023 | finance.yahoo.com

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

June 28, 2023 | finance.yahoo.com

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

June 7, 2023 | finance.yahoo.com

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

May 31, 2023 | finance.yahoo.com

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

May 16, 2023 | bizjournals.com

Autonomous delivery vehicle startup Nuro is cutting staff and production to focus on R&D

May 3, 2023 | finance.yahoo.com

NeuroMetrix Reports Q1 2023 Financial Results

April 28, 2023 | finance.yahoo.com

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

March 21, 2023 | finance.yahoo.com

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

March 14, 2023 | thestreet.com

Why NeuroMetrix (NURO) Stock Is Soaring Today

February 25, 2023 | finance.yahoo.com

NeuroMetrix Full Year 2022 Earnings: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

February 23, 2023 | finance.yahoo.com

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

February 16, 2023 | finance.yahoo.com

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

February 7, 2023 | thestreet.com

NeuroMetrix (NURO) Stock Gains After Launching Diabetes Test in Mexico

January 23, 2023 | finance.yahoo.com

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

December 11, 2022 | finance.yahoo.com

NeuroMetrix, Inc. (NURO) Stock Historical Prices & Data - Yahoo Finance

November 8, 2022 | finance.yahoo.com

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

November 3, 2022 | finance.yahoo.com

NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia

October 20, 2022 | benzinga.com

NeuroMetrix shares are trading lower after the company reported Q3 EPS and sales results were down year over year. - NeuroMetrix (NASDAQ:NURO) - Benzinga

October 20, 2022 | investing.com

NeuroMetrix Reports Q3 Loss of $0.23 By Investing.com - Investing.com

See More Headlines

Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Company Calendar

Last Earnings: 7/27/2023
Today: 9/27/2023
Next Earnings (Estimated): 10/19/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NURO
CUSIP: N/A
CIK: 1289850
Web: www.neurometrix.com
Phone: (781) 890-9989
Fax: 302-636-5454
Employees: 27
Year Founded: 1996

Profitability

EPS (Most Recent Fiscal Year): ($0.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,420,000.00
Net Margins: -75.17%
Pretax Margin: -75.17%
Return on Equity: -24.38%
Return on Assets: -22.75%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 18.42
Quick Ratio: 17.11

Sales & Book Value

Annual Sales: $7.20 million
Price / Sales: 0.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.01 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 8,585,000
Free Float: 7,941,000
Market Cap: $5.49 million
Optionable: Not Optionable
Beta: 2.28

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Shai N. Gozani M.D. (Age 58)
Ph.D., Founder, Chairman, CEO, Pres & Sec.
Comp: $437.82k

Mr. Thomas T. Higgins (Age 71)
Sr. VP, CFO & Treasurer
Comp: $342.87k

Dr. Xuan Kong Ph.D.
Chief Data Scientist

Ms. Susan M. Bell R.N.
Sr. VP of Population Health & Value Based Care

Key Competitors

View All Competitors

NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2023?: NeuroMetrix's stock was trading at $1.49 on January 1st, 2023. Since then, NURO shares have decreased by 57.1% and is now trading at $0.6390.
View the best growth stocks for 2023 here.
When is NeuroMetrix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 19th 2023.
View our NURO earnings forecast.
How were NeuroMetrix's earnings last quarter?: NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings results on Thursday, July, 27th. The medical device company reported ($0.19) EPS for the quarter. The medical device company had revenue of $1.66 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 24.38% and a negative net margin of 75.17%.
When did NeuroMetrix's stock split?: NeuroMetrix's stock reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?: 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).
What is NeuroMetrix's stock symbol?: NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."
How do I buy shares of NeuroMetrix?: Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NeuroMetrix's stock price today?: One share of NURO stock can currently be purchased for approximately $0.64.
How much money does NeuroMetrix make?: NeuroMetrix (NASDAQ:NURO) has a market capitalization of $5.49 million and generates $7.20 million in revenue each year. The medical device company earns $-4,420,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.
How can I contact NeuroMetrix?: NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.

This page (NASDAQ:NURO) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial